The EMPEROR-Preserved trial (20–22) found that SGLT-2is helped to reduce NT-ProBNP levels in patients with HFpEF, whereas the PRESERVED-HF trial (25) showed the opposite outcomes. The gene discussed is NPPB; the disease is hydrops fetalis.